Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 202

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 202
---
14,203,905 |
| Noncash increase in promissory note related to Vivus settlement                  | ​ | ​                   |           — | ​ | ​    |  10,201,758 |
| Noncash increase in inventory due to API reclass                                 | ​ | ​                   |           — | ​ | ​    |    -441,149 |
| Noncash decrease in API purchase commitment                                      | ​ | ​                   |           — | ​ | ​    |   5,918,084 |
| Noncash decrease in other current assets: API purchase commitment                | ​ | ​                   |           — | ​ | ​    |     755,554 |
| Noncash issuance of common stock to non-employee                                 | ​ | ​                   |           — | ​ | ​    |           3 |
| Noncash initial fair value of warrant liability pursuant to private placement    | ​ | ​                   |  21,544,000 | ​ | ​    |           — |
| Noncash initial fair value of derivative liability pursuant to private placement | ​ | ​                   |   6,140,000 | ​ | ​    |           — |
| Noncash redemption of Series A convertible preferred stock                       | ​ | ​                   |   1,195,743 | ​ | ​    |           — |
| Accrued Series A convertible Preferred payments payable                          | ​ | ​                   |   2,047,583 | ​ | ​    |           — |
| Accretion of Series A convertible preferred stock to redemption value            | ​ | ​                   |   4,829,755 | ​ | ​    |           — |
| Accrual of Series convertible preferred stock dividends                          | ​ | ​                   |     556,733 | ​ | ​    |           — |
| Reclass of warrant liability upon warrant modification                           | ​ | ​                   |   7,570,000 | ​ | ​    |           — |

The accompanying Notes are an integral part of the Consolidated Financial Statements.

F-7

<div align='center'>**PETROS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**</div>

**Unless the context otherwise indicates, references in these Notes to the accompanying financial statements to “we,” “us,” “our” and “the Company” refer to Petros Pharmaceuticals, Inc. (a Delaware corporation) and subsidiaries.**

1) Nature of Operations, Basis of Presentation